Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

References

Page 1

	Year	Citations
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial Jan van Lunzen, Franco Maggiolo, José Ramón Arribas, The Lancet Infectious Diseases Week ResultsTreatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2011	295
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults Sherene Min, Louis Sloan, Edwin DeJesus, AIDS	2011	212
Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin Kelly E. Dooley, Patrick Sayre, Julie Borland, JAIDS Journal of Acquired Immune Deficiency Syndromes	2012	191
Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans Stephen Castellino, Lee Moss, David S. Wagner, Antimicrobial Agents and Chemotherapy MedicineHuman RetrovirusMass BalanceAntiviral Drug DevelopmentAntiviral Therapy	2013	136
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial Kelly E. Dooley, Richard Kaplan, Noluthando Mwelase, Clinical Infectious Diseases	2019	108
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children New England Journal of Medicine	2021	106
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children Anna Turkova, Ellen White, Avy Violari, UCL Discovery (University College London)	2021	102
The tuberculosis-associated immune reconstitution inflammatory syndrome Naomi F. Walker, Cari Stek, Sean Wasserman, Current Opinion in HIV and AIDS	2018	76
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial Pauline Bollen, Cecilia L. Moore, Hilda Mujuru, The Lancet HIV	2020	46
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing BMC Infectious Diseases	2021	38

Page 1